Abstracts tagged "Osteoarthritis"

Abstract Number: 1011 • ACR Convergence 2025
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Ethan Eickmann¹, Daniel Betensky¹, Karen Smith¹, Candace Feldman¹, Jason Kim², Ankur Pandya³, Jeffrey Katz⁴ and Elena Losina⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Arthritis Foundation, Atlanta, GA, ³Harvard School of Public Health, Boston, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵BWH, Boston, MA
Background/Purpose: US federal law currently does not allow Medicare Part D coverage for weight loss medications without additional indications, such as diabetes. Several glucagon-like peptide-1…
Abstract Number: 0332 • ACR Convergence 2025
Safety, Short- and Long-Term Efficacy of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis
Mohamed Abdelsalam¹, Maryam Lasheen², Hadeer Hafez³, Bassant Elaraby Elsayed Badwy⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³⁶th October University, ⁶ october, Al Jizah, Egypt, ⁴Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Methotrexate (MTX), traditionally used for inflammatory conditions like rheumatoid arthritis, has well-established anti-inflammatory properties, recently gained interest as a potential therapeutic option for osteoarthritis…
Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: L15 • ACR Convergence 2024
LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Philip Conaghan¹, Ali Guermazi², Nathaniel Katz³, Asger Bihlet⁴, Dror Rom⁵, Michael Perkins⁶, Bernadette Hughes⁶, Claire Herholdt⁶, Iwona Bombelka⁶ and Simon Westbrook⁶, ¹University of Leeds, Leeds, United Kingdom, ²Boston University, West Roxbury, MA, ³Rin Sof Innovation, Ltd, Boston, MA, ⁴NBCD A/S, Soeborg, Denmark, ⁵Prosoft Clinical, Chesterbrook, ⁶Levicept Ltd, Ramsgate, United Kingdom
Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
Abstract Number: L04 • ACR Convergence 2024
Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images
Anders Weber¹, Mads Ammitzbøll Danielsen², Bill Aplin Frederiksen³, Hilde Berner Hammer⁴, Benjamin Schultz Overgaard³, Lene Terslev², Thiusius Rajeeth Savarimuthu⁵ and Soren Andreas Just³, ¹ROPCA, Odense, Denmark, ²Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, ³Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, ⁴Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark
Background/Purpose: To evaluate the agreement of an artificial intelligence (AI) model designed to assess greyscale and Doppler synovitis severity and osteophyte severity in hand joints…
Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: 0022 • ACR Convergence 2024
Transcriptomic Characterization of Knee Capsule Fibroblasts and Mesenchymal Stromal Cells Reveals an Association Between Flexion Contracture and Alterations in Immune Pathways in People with End-stage OA
Odette Laneuville¹, Daniel Stratis¹, Robert Feibel², Guy Trudel³ and T Mark Campbell⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Bruyère Research Institute, Ottawa, ON, Canada
Background/Purpose: Over 10% of adults have symptomatic knee OA but no disease-modifying interventions exist. A flexion contracture (loss of extension; FC) presents in 1/3 of…
Abstract Number: 0789 • ACR Convergence 2024
An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis
Xiaoqian Liu¹, Sarah Robbins¹, Jillian Eyles¹, Leticia Deveza¹, Andrew McLachlan¹ and David Hunter², ¹The University of Sydney, Sydney, New South Wales, Australia, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia
Background/Purpose: Hand osteoarthritis is a debilitating and highly prevalent disease with limited treatment options. The aim of this study was to investigate the efficacy and…
Abstract Number: 1050 • ACR Convergence 2024
The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Daniel Betensky¹, Jeffrey Katz¹, Catherine Yang², David Hunter³, Jamie Collins¹, Candace Feldman¹, Karen Smith¹, Stephen Messier⁴, Jason Kim⁵, Faith Selzer⁶ and Elena Losina¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁴Wake Forest University, Winston Salem, NC, ⁵Arthritis Foundation, Atlanta, GA, ⁶Brigham and Women's Hospital, Amesbury, MA
Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
Abstract Number: 1193 • ACR Convergence 2024
Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study
Olga Rusinovich¹, Andrea Liso Andrino², Maria Concepcion Sanchez³, Pilar Navarro Alonso⁴, Miguel Cantalejo Moreira⁵, ALBERTO DIAZ OCA⁴, Pablo Navarro Palomo⁶, Maria Machattou⁷, Maria Alonso de Francisco³, Carlota Navarro Joven⁸, Alejandro Martinez Rodado³, laura Ramos Ortiz de Zarate⁹, hildegarda Godoy Tundidor¹⁰, Maria Carmen Barbadillo Mateos⁷, Blanca Garcia-Magallon⁷, Jose Campos⁷, Mónica Fernández Castro¹¹, JESUS SANZ SANZ⁶ and Jose Luis Andreu⁶, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ³Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain, ⁴Fuenlabrada University Hospital, Fuenlabrada, Spain, ⁵Hospital Universitario de Fuenlabrada, Fuenlabrada. Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁷Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁹Puerta de Hierro Majadahonda University Hospital, Majahonda, Spain, ¹⁰Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Trapeziometacarpal osteoarthritis is a common degenerative disease that causes pain and thumb dysfunction. It affects 16-25% of the population, mainly middle-aged women. Treatment modalities…
Abstract Number: 1209 • ACR Convergence 2024
Time to Knee Replacement by Kellgren-Lawrence Grade and Presence of Frequent Knee Pain in Two Large and Diverse Longitudinal Cohorts: Data from MOST and OAI
Kent Kwoh¹, Rongrong Tang², Edward Bedrick³, Jeffery Duryea⁴, Zong-Ming Li², Jean Liew⁵, Xiaoxiao Sun⁶ and Tuhina Neogi⁵, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, University of Arizona College of Medicine - Tucson, Tucson, AZ, ³Department of Epidemiology andBiostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ
Background/Purpose: Receipt of knee replacement has been proposed by the FDA as a structural and symptom outcome for clinical trials of Disease Modifying Osteoarthritis Drugs…
Abstract Number: 1665 • ACR Convergence 2024
Multicenter Randomized Controlled Trial of Physical Therapy (PT) or Sham PT in Persons with Knee Pain, Meniscal Tear, and Osteoarthritic Imaging Changes
Jeffrey Katz¹, Jamie Collins², Leslie Bisson³, Faith Selzer⁴, Morgan Jones², Heidi Yang², James Irrgang⁵, Clare Safran-Norton², Kurt Spindler⁶ and Elena Losina², ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³University at Buffalo, Buffalo, NY, ⁴Brigham and Women's Hospital, Amesbury, MA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Cleveland Clinic, Clev, OH
Background/Purpose: The syndrome of knee pain and meniscal tear (MT) is prevalent and disabling. The TeMPO trial (Treatment of Meniscal Problems in Osteoarthritis (OA)) compares…
Abstract Number: 2089 • ACR Convergence 2024
Diagnostic Performance of ACR and NICE Criteria for Hip Osteoarthritis
Jos Runhaar¹, Dieuwke Schiphof¹, Qiuke Wang¹, Margreet Kloppenburg², Maarten Boers³, Hans Bijlsma⁴ and Sebastia Bierma-Zeinstra¹, and the CREDO expert group, ¹Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁴UMCU, Utrecht, Utrecht, Netherlands
Background/Purpose: Available criteria for diagnosis or classification of hip osteoarthritis (OA) have been poorly validated. The few validation studies available all used radiographic features of…
Abstract Number: 2105 • ACR Convergence 2024
The Identity, Impact, and Management of OA and OA Pain from the Perspective of People with OA: A Systematic Literature Review of Qualitative Studies
Sylvain Mathieu¹, Alice Courties², Céline Mathy³, Serge Perrot⁴, Françoise Alliot Launois⁵, Stan Moumbe⁶, Nathan Foulquier⁷, Jérémie Sellam⁸ and Rinie Geenen⁹, and GO-PAIN Working group, ¹CHU Gabriel Montpied, Clermont-Ferrand, France, ²AP-HP, Paris, France, ³University of Liège, Liège, Belgium, ⁴Paris Dauphine University, Paris, France, ⁵AFLAR, Paris, France, ⁶Patient, Paris, France, ⁷LBAI. UMR 1227, University of Brest, Brest, France, ⁸Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ⁹Department of Psychology, Utrecht, Netherlands
Background/Purpose: Knowledge of beliefs, needs, and priorities of people with osteoarthritis (OA) is of utmost important to be able to offer person-centered care. Concepts that…
Abstract Number: 0023 • ACR Convergence 2024
Adenosine and Guanosine-based Oligonucleotide Attenuates Catabolic Phenotypes in Chondrocytes and Slows Progression of Surgically Induced Osteoarthritis
Yoonhee Kim¹, Jin Han² and Seungwoo Han³, ¹Kyungpook National University School of Medicine, Buk-gu, Daegu, Republic of Korea, ²Kyungpook National University, Buk-gu, Daegu, Republic of Korea, ³Kyungpook national university hospital, Daegu, South Korea
Background/Purpose: Adenosine is a potent endogenous modulator of inflammation; however, its clinical application is limited due to its extremely short half-life in blood. In this…

« Previous Page
1
…
7
8
9
10
11
…
71
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].